Olmetec (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmetec, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension and is indicated for use in adults who require blood pressure control. GNH USA supplies Olmetec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmetec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an ARB that lowers blood pressure by acting on the renin‑angiotensin system. - Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes. - Heart failure: used as part of combination therapy to improve outcomes in patients with reduced ejection fraction.

Olmesartan medoxomil is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevations

When prescribing Olmesartan medoxomil, clinicians should consider several safety aspects. - Pregnancy: contraindicated due to risk of fetal toxicity. - Renal impairment: monitor kidney function and adjust therapy as needed. - Hyperkalemia risk: check serum potassium, especially with potassium‑sparing diuretics. - Drug‑induced hypotension: advise patients to rise slowly from sitting or lying positions. - Concomitant NSAIDs: may reduce antihypertensive effect and affect renal function. Store below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan medoxomil can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase risk of renal dysfunction, hyperkalemia, and hypotension. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): can blunt antihypertensive response and affect renal function. - Lithium: may increase lithium levels, risking toxicity. - ACE inhibitors: concurrent use raises risk of hypotension, hyperkalemia, and renal impairment.